Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Approval for New Clinical Manufacturing Site

Published: Thursday, July 18, 2013
Last Updated: Thursday, July 18, 2013
Bookmark and Share
Completes successful MHRA inspection.

UK-BASED contract research and manufacturing organization Molecular Profiles has opened the doors of its new facility following a successful inspection from the Medicines and Healthcare products Regulatory Agency (MHRA).

The Nottingham-based, £9 million pharmaceutical production site will give drug development companies across the world access to the clinical manufacturing capabilities.

Designed to handle a range of non-sterile dosage forms such as solids, liquids, semi-solids and inhaled products, Molecular Profiles’ new 30,000sq ft. facility marks a significant expansion for the company that started life as a spin-out from Nottingham University over 15 years ago.

The investment adds six GMP suites, new laboratories and a dedicated clinical packing area to support clients’ Phase I and II clinical trial projects.

The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with manufacturing batch scale of up to 30kg.

Nikin Patel, CEO at Molecular Profiles, said: “Receiving our license from the MHRA for our new site is probably the biggest milestone for our business since we set-up shop so is naturally a very exciting time for everyone involved.

“From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements.”

The official approval of the company’s cGMP-compliant facility follows a recent high-profile visit from the Honourable Nick Clegg, Deputy Prime Minister of the UK Government, which provided £1.6m to the expansion through the regional growth fund grant.

The company’s vice president Steve Kemp added: “We have enjoyed a sustained and gradual period of growth over the last decade driven by our consulting, formulation development and analytical services but we are expecting our expanded manufacturing facilities to take us to the next level by helping us better compete on a global scale.”

Having a dedicated manufacturing site complements Molecular Profiles’ established formulation development expertise.

Furthermore, it supports its strategic alliance with Onyx Scientific, which is aimed at delivering end-to-end pharmaceutical development services from initial drug discovery through to the later phases of clinical development.

Founded by a group of scientists, Molecular Profiles now works with leading pharmaceutical companies across the globe and specializes in advanced characterization, R&D and manufacturing services.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Profiles, Xceleron Drug Development Partnership
Companies announce a collaboration to assist drug developers with improved efficiency during clinical development.
Saturday, November 01, 2014
Molecular Profiles Strengthens Capsule Capability
Adds capsule bander for liquid filling and a second capsule filling machine.
Thursday, September 11, 2014
Molecular Profiles, XenoGesis Collaborate
Partnership will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.
Monday, August 04, 2014
Molecular Profiles Joins Leading Consortium to Drive Paediatric Formulation Development
UK-wide consortium has received a £660k grant from the Technology Strategy Board.
Friday, December 27, 2013
Molecular Profiles and Onyx Scientific Form Strategic Alliance
New alliance offers fully integrated services from drug discovery through to late phase clinical trial manufacturing.
Tuesday, August 14, 2012
CEO of Molecular Profiles Recognized as One of 100 Most Inspiring People in the Life Sciences Industry
Nikin Patel has been acknowledged as one of PharmaVOICE magazine's top 100 most inspiring individuals in the life sciences industry.
Tuesday, August 09, 2011
Molecular Profiles Expands Service Offering with new Manufacturing Capabilities
The manufacturing capabilities enables the company to handle larger projects for pharmaceutical clients from preformulation through to Phase IIa.
Tuesday, January 18, 2011
Molecular Profiles Wins the Queen’s Award for Enterprise in 2007 in the Category of Innovation
The award recognizes Molecular Profiles’ contract research services which encompass the company’s knowledge and skills in advanced analytical techniques.
Monday, April 23, 2007
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos